Skip to main content
. 2019 Apr 2;9:210. doi: 10.3389/fonc.2019.00210

Figure 4.

Figure 4

TET2 mutations as background mutations. Thanks to TET2 mutations as background mutations, the disease will occur and develop by the accumulation of additional mutations. In the first example (42), TET2-D1384V in HSCs, then in NPM1 and FLT3 mutation, induced an AML. In the second example (31, 44), TET2 mutation with JAK2V617F-positive generated thrombocythemia, which can transform into secondary myelofibrosis due to an additional ASXL1 mutation. In the third example (23), mutations in SRSF2, then in KRAS mutation developed a chronic myelomonocytic leukemia (CMML).